Arbutus receives $178M from Moderna settlement, files patent suits against Pfizer/BioNTech, plans $230M share repurchase

Arbutus Biopharma Corp

Received approximately $178M from Moderna as its share of noncontingent settlement payment on July 8, 2026.
Filed three international patent infringement lawsuits against Pfizer/BioNTech in Canada and UPC seeking injunctions and damages.
Entered termination agreement with Genevant for RSV agreement, with Genevant paying $1.0M termination fee.
Approved one-time cash bonuses for CEO Lindsay Androski (1.5% of $178M) and CFO Tuan Nguyen (0.25% of proceeds).
Plans to return up to $230M to shareholders via share repurchases in Q3 2026 after receiving dividend from Genevant parent.

Featured in Daily 8-K Digest

Selected #4 for 2026-07-16. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.